Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) and Trulieve Cannabis (NYSE:TRLV – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.
Profitability
This table compares Aquestive Therapeutics and Trulieve Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aquestive Therapeutics | -162.33% | N/A | -57.35% |
| Trulieve Cannabis | -41.22% | -0.34% | -0.14% |
Insider & Institutional Ownership
32.5% of Aquestive Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings for Aquestive Therapeutics and Trulieve Cannabis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aquestive Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
| Trulieve Cannabis | 1 | 1 | 1 | 0 | 2.00 |
Aquestive Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 144.41%. Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 33.39%. Given Aquestive Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Trulieve Cannabis.
Valuation & Earnings
This table compares Aquestive Therapeutics and Trulieve Cannabis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aquestive Therapeutics | $44.54 million | 10.10 | -$83.78 million | ($0.64) | -5.59 |
| Trulieve Cannabis | $1.18 billion | 1.83 | -$116.38 million | $0.20 | 56.22 |
Aquestive Therapeutics has higher earnings, but lower revenue than Trulieve Cannabis. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.
Summary
Aquestive Therapeutics beats Trulieve Cannabis on 8 of the 12 factors compared between the two stocks.
About Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.
About Trulieve Cannabis
Trulieve Cannabis Corp. is a U.S. cannabis company that cultivates, processes and sells cannabis products through a vertically integrated business. Its offerings include flower, concentrates, vape products, edibles and other cannabis products, sold under brands such as Trulieve and Modern Flower. Founded in Florida in 2015, the company built its business in that state and expanded into other U.S. markets, including Arizona and Pennsylvania. Its operations and product offerings are shaped by the regulations in each state where it operates.
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
